Research Progress of Soluble sST2 in Heart Failure after Acute Myocardial Infarction

sST2是由ST2基因编码的一种蛋白质，包括跨模型受体和可溶性ST2 (sST2)两种亚型。ST2L可与IL-33特异性结合形成跨膜复合物，参与体内多个系统炎症和免疫性疾病的发生、发展，而sST2可作为诱骗受体与IL-33结合，阻断IL-33/ST2L信号通路。近年来，多种研究发现，sST2在急性心梗后心衰患者中的早期预测、诊疗、危险分层中起到重要作用。是可联合NT-pro BNP及肌钙蛋白应用于急性心梗后心衰早期诊断的一个新型标志物。本文系统回顾sST2在急性心梗后心衰的临床应用研究进展，以期为早期诊断、积极干预、改善病人预后及生存质量方面提供新的思路。sST2 is a protein encoded by the ST2 gene, which includes two subtypes, trans-body and soluble ST2 (sST2). ST2L can specifically bind to IL-33 to form a transmembrane complex and participate in the occurrence and development of multiple systemic inflammatory and immune diseases in vivo, while sST2 can act as a decoy receptor to bind to IL-33 and block the IL-33/ST2L signaling pathway. In recent years, a variety of studies have found that sST2 can be used in the early prediction, diagnosis and treatment, and risk stratification of patients with heart failure after acute myocardial infarction. It is a novel marker that can be used in combination with NT-pro BNP and troponin for the early diagnosis of heart failure after acute myocardial infarction. This article systematically reviews the research progress of the clinical application of sST2 in heart failure after acute myocardial infarction, in order to provide new ideas for early diagnosis, active intervention, and improvement of prognosis and quality of life of patients.